FDA Medical Device: Non-Invasive Cervical Cancer Detection (OTC:GTHP.OB)

Guided Therapeutics, Inc. (OTC:GTHP) contains perhaps one of the most promising medical devices aiming for an annual global $1 billion dollar non-invasive cervical cancer market. Their device, LightTouch, is a powerful and innovative non-invasive screening instrument for early detection of cervical cancer.

Now, lets take a look at how Guided Therapeutics, Inc. sits alongside the likes of Nephros (OTC:NEPH) and Imaging3 (OTC:IMGG); but before getting started, lets dust our shoulders off right off the bat and address an important issue which is rarely discussed: One problem that many rookie investors will argue these days is, the price per share for a stock; within the small cap industry, everyone seems to be lovestruck by stocks worth under the fifty cent mark, without even considering the current market cap, outstanding shares, and the market potential of the product being developed and/or released for distribution.

This is where GTHP comes in, it has one notable difference which separates it from the others, and that is the highly undervalued market cap of GTHP relative to its product.

When taking a look at the respective market caps of IMGG ($173M), and NEPH($53M), it then becomes evidently clear that GTHP’s highly conservative (11M) will undoubtedly follow in the foot steps of these golden nuggets.

GTHP’s product, LightTouch, is indeed impressive when taking into consideration that there exists only two other screening options for cervical cancer detection in the Pap smear and HPV tests, which are painful, and highly inaccurate procedures.

GTHP had its product tested on over 3000 women to date, and over 1900 in a critical FDA pivotal clinical trial on route to providing a 46% improvement over the Pap smear test, and thus leading to the company receiving a multi-million dollar grant from the National Cancer Institute on 10/5/09. Based on the outcome of the study, GTHP plans to submit the trial results to the FDA as part of the Premarket Approval (PMA) application for the LightTouch.

Undervalued and high potential couldn’t be more evident for GTHP. A company that with its recent $2.5M grant from the National Cancer Institute has come a long way from bankruptcy fears stated in the 08/18/2009 10-Q. Oh, and it doesn’t hurt when 81% of women want the LightTouch to replace the current conventional Pap smear.

If anyone is wondering why they mention SpectRx in the study, it is because that was the old name prior to their name change to Guided Therapeutics.

The full special report on the company appears today at http://www.stockshaven.com/fda-medical-device-non-invasive-cervical-cancer-detection-otcgthp/


Disclosure: Short-term position in GTHP


To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About StocksHaven Investments

StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

Michael Vlaicu

Founder and Lead Investment Analyst

StocksHaven Investments

Contact via E-mail